We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Partially Grants Keryx’s Exclusivity Requests for Auryxia
FDA Partially Grants Keryx’s Exclusivity Requests for Auryxia
While the FDA shot down Keryx Biopharmaceuticals’ request for five-year new chemical entity (NCE) exclusivity for its Auryxia (ferric citrate) oral tablets, it OK’d the drugmaker’s petition for three-year exclusivity.